Related Experiment Videos
[Longitudinal study of children with bronchopulmonary dysplasia treated with disodium cromoglycate]
Barbara Kassur-Siemieńska1, Bogumiła Milewska-Bobula, Hanna Dmeńska
1Klinika Niemowleca, Instytut "Pomnik Centrum Zdrowia Dziecka", Warszawa.
Insights
Disodium cromoglycate effectively treated bronchopulmonary dysplasia (BPD) in premature infants, significantly reducing obstructive bronchitis and improving blood-gas normalization. This offers a promising therapeutic option for chronic lung disease in neonates.
Area of Science:
- Pediatric Pulmonology
- Neonatology
- Pharmacology
Context:
- Bronchopulmonary dysplasia (BPD) is a chronic lung disease affecting premature infants.
- Improving quality of life for premature infants with BPD is a clinical challenge.
- Existing treatments often involve corticosteroids, with potential side effects.
Purpose:
- To evaluate the efficacy of disodium cromoglycate in treating BPD in infants.
- To compare outcomes in infants treated with disodium cromoglycate versus standard care.
- To assess the drug's impact on recurrent obturative bronchitis and bronchial hyperresponsiveness.
Summary:
- A retrospective study compared 15 premature infants with BPD treated with disodium cromoglycate to 11 controls.
- All infants experienced recurrent obturative bronchitis and bronchial hyperresponsiveness.
- The disodium cromoglycate group showed statistically significant improvement in bronchitis regression and blood-gas normalization.
Impact:
- Disodium cromoglycate demonstrates significant efficacy in managing BPD-related respiratory issues in premature infants.
- This finding suggests a potential alternative or adjunctive therapy for chronic lung disease in neonates.
- Further research into disodium cromoglycate for BPD management is warranted.
Abstract:
In order to improve the quality of life of children born prematurely, who developed chronic lung disease, clinical trials of drugs of different origin are undertaken. The aim of the work was the evaluation of the efficacy of disodium cromoglycate in the treatment of bronchopulmonary dysplasia in children. We retrospectively studied 15 infants with bronchopulmonary dysplasia (BPD) hospitalised in the Infant Care Department of Children's Health Memorial Institute from 01.01.1997 to 01.02.2000. All babies were premature (25-30 weeks of gestation) with LBW or VLBW A control group of 11 babies with BPD, matched for birth weight and gestational age, who did not have disodium cromoglycate therapy were also studied. Recurrent obturative bronchitis and bronchial hyperresponsiveness were stated in all cases in both groups. Disodium cromoglycate was administered in all babies in the study group. Inhaled corticosteroid (Budesonide mite) was given in 10 cases, for a short period of time, due to severe obturative bronchitis. Babies in the control group were treated with systemic and inhaled corticosteroids. Results of our trial compared with the log-rank and chi2 test show statistically, significant differences in the regression of obturative bronchitis (log-rank = 4.35, p < 0.0001) and normalization of capillary blood-gas examination (log-rank = 3.777, p < 0.0002) in favour of the studied group, treated with disodium cromoglycate.
Related Concept Videos
COPD: Management Using Bronchodilators and Corticosteroids
Chronic Obstructive Pulmonary Disease-IV: Assessement and Diagnostic Studies
Medical History
Chronic Obstructive Pulmonary Disease-V: Management
Smoking Cessation
Chronic Obstructive Pulmonary Disease III: Chronic Bronchitis Features
Chronic Obstructive Pulmonary Disease
Smoking is a primary risk factor for COPD, with over 80% of patients having a history of it. Patients typically experience progressive dyspnea or labored breathing, frequent coughing, and recurrent pulmonary infections. Many eventually succumb to respiratory failure, characterized by...
Chronic Obstructive Pulmonary Disease-V: Nursing Management
Assessment